A process for isolating cells of interest from a sample comprising polluting cells. The process includes a filtration step through a membrane provided with pores and with linkers, and a crosslinking step allowing to bind the polluting cells to the membrane, leaving the cells of interest unbound.

An object of the present invention is to provide a kit, a method, and a reagent which prevent the problem of false positive due to nonspecific adsorption, suppress the increase in noise to be generated, and are capable of achieving high-precision measurement of progesterone in a wide concentration range from a low concentration to a high concentration, in the measurement of progesterone in a biological sample. The present invention provides a progesterone measuring kit including a first particle having a label and modified with a first binding substance, a second particle having no label and modified with a second binding substance, a flow channel, and a substrate, in which the first particle contains a compound represented by Formula (1) and a particle, and an average particle diameter of the first particles is 50 to 250 nm, an average particle diameter of the second particles is 70 to 500 nm, and the average particle diameter of the second particles is larger than the average particle diameter of the first particles.

##STR00001##

Each symbol in the formula has the meaning described in the present specification.

An object of the present invention is to provide a kit, a method, and a reagent which prevent the problem of false positive due to nonspecific adsorption, suppress the increase in noise to be generated, and are capable of achieving high-precision measurement of progesterone in a wide concentration range from a low concentration to a high concentration, in the measurement of progesterone in a biological sample. The present invention provides a progesterone measuring kit including a first particle having a label and modified with a first binding substance, a second particle having no label and modified with a second binding substance, a flow channel, and a substrate, in which the first particle contains a compound represented by Formula (1) and a particle, and an average particle diameter of the first particles is 50 to 250 nm, an average particle diameter of the second particles is 70 to 500 nm, and the average particle diameter of the second particles is larger than the average particle diameter of the first particles.

##STR00001##

Each symbol in the formula has the meaning described in the present specification.

Methods for identifying or monitoring or treating HIV persistence or the development of an HIV-comorbidity in an HIV+ subject involve certain selected glycan dysregulations. In certain embodiments, hyposialylation in the total IgG glycome or total plasma glycome of an HIV+ subject during or after antiretroviral therapy is an indication of HIV persistence and can be predictive of developing co-morbidities. Methods of treating HIV persistence or preventing developing co-morbidities involves modifying or manipulating the selected glycan by administering therapeutic agents that will modify the levels of the selected glycan, a precursor thereof, or another component of its pathway.

Detection rapidly and with high detection intensity is accomplished while blackening is inhibited during silver enhancement to detect an analyte in a specimen. One embodiment of the present invention provides an enhancing agent to be used for silver enhancement in detection of an analyte in a specimen by metal labeling and silver enhancement, the enhancing agent including: (a) a silver-containing compound, (b) a silver ion-reducing agent, and (c) a reaction rate controller,
wherein the reaction rate controller (c) is a compound selected from the group consisting of compounds represented by the following formula (I):

##STR00001##

(wherein: R.sup.1, R.sup.2 and R.sup.3 each independently represent a hydrogen atom or an optionally substituted monovalent aliphatic hydrocarbon group of 1 to 30 carbon atoms, with the proviso that R.sup.1, R.sup.2 and R.sup.3 are not all hydrogen atoms, or R.sup.1 and R.sup.2 form a 5-membered ring or 6-membered ring and R.sup.3 represents a hydrogen atom or an optionally substituted monovalent aliphatic hydrocarbon group of 1 to 30 carbon atoms; X represents a divalent hydrocarbon group of 1 to 3 carbon atoms; and n is an integer of 1 to 3).

A particle including a polymer which has a repeating unit derived from a vinyl-based monomer. The particle has a specific structure containing a carboxy group, and a surface of the particle contains a water-soluble polymer.

A particle including a polymer which has a repeating unit derived from a vinyl-based monomer. The particle has a specific structure containing a carboxy group, and a surface of the particle contains a water-soluble polymer.

The invention provides methods and compositions for treating attention-deficit/hyperactivity disorder (ADHD) in an individual. The methods provided herein entail administering a composition comprising an isolated Mycobacterium or antigenic fragments derived therefrom. Also provided herein are methods for assessing alleviation of symptoms and/or alteration of immune system functioning following administration of a composition comprising an isolated Mycobacterium or antigenic fragments derived therefrom.

The invention provides methods and compositions for treating attention-deficit/hyperactivity disorder (ADHD) in an individual. The methods provided herein entail administering a composition comprising an isolated Mycobacterium or antigenic fragments derived therefrom. Also provided herein are methods for assessing alleviation of symptoms and/or alteration of immune system functioning following administration of a composition comprising an isolated Mycobacterium or antigenic fragments derived therefrom.

Provided are a fusion protein comprising an antibody binding area and an endocytic functional area, the encoding nucleic acid of the protein, an expression vector of same, a host cell thereof, and an immune effector cell expressing the fusion protein or the endocytic functional area or further expressing a chimeric antigen receptors. Also provided are an immunoconjugate comprising a cell-killing part and an antibody conjugate in a specifically-binding immune effector cell or an antibody of the endocytic functional area, a reagent kit and uses of the immunoconjugate, and a method for specifically removing, selecting, or enriching and detecting the immune effector cell.